Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05130567 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of LP-128 Capsules in Healthy Subjects

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 3, 2025 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 30, 2024 to Sep 30, 2026 Completion date: Dec 30, 2024 to Dec 30, 2026v8 Show 1 more changeShow less
    • Completion date: Dec 30, 2024 to Dec 30, 2026
  2. Primary completion date: Dec 30, 2023 to Dec 30, 2024 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 31, 2023 to Dec 30, 2024 · Site details revisedv7 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 31, 2023 to Dec 30, 2024
    • Site details revised
  3. Primary completion date: Jun 30, 2023 to Dec 30, 2023v6
  4. Primary completion date: Dec 31, 2022 to Jun 30, 2023 Enrollment target: 90 to 104 · Completion date: Mar 31, 2023 to Dec 31, 2023v5 Show 2 more changesShow less
    • Enrollment target: 90 to 104
    • Completion date: Mar 31, 2023 to Dec 31, 2023
  5. Primary endpoints revised (4) Enrollment target: 88 to 90 · Primary completion date: Oct 31, 2022 to Dec 31, 2022 · Completion date: Dec 31, 2022 to Mar 31, 2023 · 4 morev4 Show 7 more changesShow less
    • Enrollment target: 88 to 90
    • Primary completion date: Oct 31, 2022 to Dec 31, 2022
    • Completion date: Dec 31, 2022 to Mar 31, 2023
    • Secondary endpoints: 5 to 2
    • Study description shortened, about 6 words
    • Study arms: 6 to 4
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Jun 15, 2022 to Oct 31, 2022 Completion date: Jul 30, 2022 to Dec 31, 2022v3 Show 1 more changeShow less
    • Completion date: Jul 30, 2022 to Dec 31, 2022
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 15, 2021 to Nov 19, 2021 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Nov 15, 2021 to Nov 19, 2021
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LP-128 Capsules After Single- and Multiple-Dose in Healthy Subjects
Trial Details
NCT Number NCT05130567
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions Chronic Hepatitis b
Enrollment 104 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov